

# EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Results of a 28-day Phase 1b Study in NUC-suppressed CHB Patients

Jordan J. Feldt, Eric Lawitz, Tuan Nguyen, Jacob Lalazar, Tarek Hassanein, Paul Martin, Steven-Huy Han, Douglas Dieterich, Jeanne-Marie Giarr, Guy De La Rosa, Alan Ahmad, Ed Luo, Annie L. Conery, Nathalie Adde  
 Toronto Centre for Liver Disease, University Health Network, Toronto, Canada, Texas Liver Institute, San Antonio, Texas, USA, Thien Nguyen MD Gastroenterology and Hepatology, San Diego, California, USA, Quest Clinical Research, San Francisco, California, USA, Southern California Research Center, Coronado, California, USA, Gastroenterology, University of Miami, Florida, USA, University of California, Los Angeles, Los Angeles, California, USA, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA, Centre Hospitalier Universitaire de Montreal, Montreal, Quebec, Canada, Enanta Pharmaceuticals, Inc., Watertown, Massachusetts, USA

# ENANTA Pharmaceuticals

822

## INTRODUCTION

Chronic hepatitis B virus (HBV) infection is a global public health challenge, with estimates of more than 296 million HBV carriers worldwide, of whom approximately 820,000 die annually from HBV-related liver disease. There is an unmet medical need for curative therapy, i.e., a finite treatment which yields a sustained post-treatment response.

EDP-514 is a novel class II HBV core inhibitor. EDP-514 inhibits HBV replication with an *in vitro* EC<sub>50</sub> of 18, 27 and 17 nM in HepAD38, HepDE19, and HepG2.2.15 cells, respectively, and a >4-log viral load reduction in HBV-infected chimeric mice with human liver cells. EDP-514 was shown to be generally safe and well tolerated over a broad range of single and multiple doses for up to 14 days in healthy adult subjects. Here, we present results of a Phase 1b, 28-day study in non-cirrhotic, HBeAg(+) or (-) Chronic Hepatitis B (CHB) patients virologically suppressed on Nucleos(t)ide (NUC) therapy.


## METHODS

### Study Design

Eight subjects per cohort were randomized 3:1 to receive multiple once-daily oral doses of either EDP-514 at 200, 400, and 800 mg doses or placebo for 28 days.

The first cohort received 200 mg of EDP-514 and cohort progression was determined by a Study Adjudication Committee after review of blinded safety and available PK data.

### Study Design



### Key Objectives

- Primary**
  - To evaluate the safety and tolerability of multiple doses of EDP-514 to augmented to NUC-suppressed CHB patients
- Secondary**
  - To evaluate the plasma PK of multiple doses of EDP-514 of NUC-suppressed CHB patients
  - To evaluate the antiviral activity of multiple doses of EDP-514 in NUC-suppressed CHB patients

### Key Inclusion/Exclusion Criteria

- Inclusion Criteria:**
  - Male and female subjects of any ethnic origin between the ages of 18 and 70 years
  - CHB subjects must have HBeAg detectable at screening and in most recent test at least 6 months prior
  - Screening HBV DNA < LLOQ and no HBV DNA ≥ LLOQ over previous 12 months
  - No change in HBV NUC treatment regimen for 12 months prior to screening
- Exclusion Criteria:**
  - Documented prior diagnosis of cirrhosis
  - Documented extensive bridging fibrosis or cirrhosis
  - Evidence of hepatocellular carcinoma by imaging or screening AFP ≥ 50 ng/mL
  - Meeting defined safety laboratory parameters at screening
  - Coinfection with HIV, HAV, HCV, HDV, or HEV
  - Chronic liver disease of non-HBV etiology

### Assessments

- Safety and tolerability assessments**
  - Adverse events, clinical laboratory tests, physical examinations, vital signs, and electrocardiograms
- PK assessments**
  - On Days 1 and 28, blood samples were collected at predose and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
  - On Days 3, 7, 14 and 21, blood samples were collected at predose, 1-3 hrs postdose and at least 1 hr after the first postdose sample and prior to next dose
  - Concentrations of EDP-514 and its metabolites were measured using a validated method
  - PK parameters were determined using non-compartmental methods in Phoenix WinNonlin (Pharsight Corporation)
- Antiviral activity assessments**
  - HBV DNA levels
  - Incidences of virologic failure defined as HBV DNA level ≥ LLOQ and which is confirmed to be ≥ LLOQ on repeat testing

## RESULTS

### Subject Disposition and Demographics

- A total of 24 subjects were enrolled in the study
  - One subject from the EDP-514 200 mg arm discontinued from the study due to an adverse event of upper abdominal pain
  - Subjects were mostly male, Asian, HBeAg(-), with a mean age of 45 years, mean HBV DNA of 1.67 IU/mL, and mean HBV RNA of 1.13 log U/mL at baseline

Subject demographics and disease characteristics are summarized in Table 1

Table 1. Baseline Demographics and Disease Characteristics

	200 mg QD (N=6)	400 mg QD (N=6)	800 mg QD (N=6)	Placebo (N=6)	Overall (N=24)
Sex [n (%)]					
Female	4 (66.7)	0	4 (66.7)	1 (16.7)	9 (37.5)
Male	2 (33.3)	6 (100)	2 (33.3)	5 (83.3)	15 (62.5)
Race [n (%)]					
White	1 (16.7)	1 (16.7)	1 (16.7)	3 (50.0)	6 (25.0)
Black or African American	0	2 (33.3)	0	0	2 (8.3)
Asian	5 (83.3)	3 (50.0)	5 (83.3)	3 (50.0)	16 (66.7)
Ethnicity [n (%)]					
Not Hispanic or Latino	6 (100)	6 (100)	6 (100)	6 (100)	24 (100)
Age (yr) <sup>a</sup>	43.2 (25, 62)	41.8 (34, 52)	43.0 (31, 49)	52.7 (45, 61)	45.2 (25, 62)
BMI (kg/m <sup>2</sup> ) <sup>a</sup>	24.46 (18.3, 31.1)	27.22 (23.5, 34.6)	26.81 (24.8, 31.0)	28.09 (23.0, 34.4)	26.64 (18.3, 34.6)
HBeAg negative [n (%)]	5 (83.3)	5 (83.3)	5 (83.3)	6 (100)	21 (87.5)
HBV DNA (IU/mL) <sup>b</sup>	2.50 (0.0, 10.0)	2.50 (0.0, 5.0)	1.67 (0.0, 5.0)	0.00 (0.0, 0.0)	1.67 (0.0, 10.0)
HBV RNA (Log U/mL) <sup>c</sup>	1.18 (0.0, 2.5)	1.57 (0.0, 3.7)	0.83 (0.0, 4.2)	0.96 (0.0, 2.1)	1.13 (0.0, 4.2)
HBV RNA < LOD [n (%)] <sup>c</sup>	3 (50.0)	2 (33.3)	5 (83.3)	4 (66.7)	14 (58.3)
Tenofovir (TAF/TDF) [n (%)]	5 (83.3)	5 (83.3)	6 (100)	6 (100)	22 (91.7)

a. Presented as Mean (Min, Max), b. HBV DNA Limit of Detection = 10 IU/mL, c. HBV RNA Limit of Detection = 1.65 Log U/mL  
 BMI = Body Mass Index, QD = Once Daily, yr = Year, TAF = tenofovir alafenamide, TDF = tenofovir disoproxil fumarate

### Pharmacokinetics


- EDP-514 exposure increased with increasing multiple doses, with time-linear pharmacokinetics (Table 2, Figure 2)
- Exposures of EDP-514 increased with multiple dosing with an accumulation index of ~1.3
- PK supportive of once daily dosing, with median C<sub>rough</sub> at Day 28 ~16-fold for 200 mg, ~18-fold for 400 mg, and ~21-fold for 800 mg the protein-adjusted EC<sub>50</sub>

Table 2. EDP-514 Day 28 Plasma PK Parameters

PK Parameters	200 mg QD (N=6)	400 mg QD (N=6)	800 mg QD (N=6)
AUC <sub>0-24</sub> (ng/mL*hr) <sup>a</sup>	17498 (11.8)	22438 (19.5)	39331 (19.8)
C <sub>max</sub> (ng/mL) <sup>a</sup>	3405 (11.5)	4048 (14.9)	7495 (21.9)
C <sub>rough</sub> (ng/mL) <sup>b</sup>	1110 (860-1150)	1245 (1080-1700)	1465 (1100-2850)

a. Data presented as Mean (SD)  
 b. Data presented as Median (Interquartile Range)  
 N=6, except for 200 mg AUC<sub>0-24</sub>, C<sub>max</sub>, and C<sub>rough</sub> N=5

Figure 2. Mean Plasma PK Concentrations vs. Time Following Oral Administration of EDP-514 at Day 1 and Day 28



## Safety


- Overall, EDP-514 was generally safe and well-tolerated in 200, 400 and 800 mg doses (Table 3)
- Eight patients reported treatment emergent adverse events (TEAEs); all were mild except for 1 moderate event (upper abdominal pain) in the EDP-514 200 mg arm that led to study drug discontinuation, and 1 severe event (drug hypersensitivity [allergic reaction to aloe cream]) in the EDP-514 800 mg arm that was unrelated to study drug
- There were no Grade 4 or serious TEAEs
- There were no clinically significant laboratory abnormalities, including no clinically significant ALT/AST elevations or notable differences in mean (+/- SD) change from baseline of all arms (Figure 3), and no clinically meaningful changes in ECG or vital signs

Table 3. Summary of TEAEs Following Administration of EDP-514 in the MAD Phase

System Organ Class Preferred Term [n (%)]	200 mg QD (N=6)	400 mg QD (N=6)	800 mg QD (N=6)	Placebo (N=6)	Overall (N=24)
Total Subjects with at Least One TEAE	5 (83.3)	1 (16.7)	2 (33.3)	0	8 (33.3)
<b>Gastrointestinal disorders</b>					
Nausea	1 (16.7)	1 (16.7)	0	0	2 (8.3)
Abdominal pain upper	1 (16.7)	0	0	0	1 (4.2)
Diarrhoea	1 (16.7)	0	0	0	1 (4.2)
<b>Investigations</b>					
Blood creatine phosphokinase increased	0	0	2 (33.3)	0	2 (8.3)
Neutrophil count decreased	0	0	1 (16.7)	0	1 (4.2)
White blood cell count decreased	0	0	1 (16.7)	0	1 (4.2)
<b>Nervous system disorders</b>					
Dizziness	1 (16.7)	0	0	0	1 (4.2)
Headache	0	1 (16.7)	0	0	1 (4.2)
<b>Respiratory, thoracic and mediastinal disorders</b>					
Hyperventilation	1 (16.7)	0	0	0	1 (4.2)
Rhinorrhoea	1 (16.7)	0	0	0	1 (4.2)
<b>General disorders and administration site conditions</b>					
Fatigue	1 (16.7)	0	0	0	1 (4.2)
<b>Immune system disorders</b>					
Drug hypersensitivity	0	0	1 (16.7)	0	1 (4.2)
<b>Infections and infestations</b>					
Urinary tract infection	1 (16.7)	0	0	0	1 (4.2)
<b>Skin and subcutaneous tissue disorders</b>					
Pruritus	1 (16.7)	0	0	0	1 (4.2)
<b>Vascular disorders</b>					
Flushing	1 (16.7)	0	0	0	1 (4.2)

n = Number of Subjects  
 \*Occurred in same subject, \*\*Occurred in same subject

Figure 3. ALT and AST Mean (+/- SD) from Baseline Over Time



## Antiviral Activity

- At Day 28, mean HBV RNA change of -0.81, -1.12, 0.10, and -0.19 log U/mL were observed in the 200 mg, 400 mg, 800 mg and placebo groups, respectively (Table 4, Figure 4)
- EDP-514 led to a maximum HBV RNA reduction of 2.3 log in HBeAg(-) and 2.8 log in HBeAg(+) subjects in EDP-514 arms compared to 1.2 log in placebo
- For the EDP-514 800 mg subjects, 5 of 6 subjects had either non-detectable or very low levels of HBV RNA at baseline; consequently, the effect of EDP-514 on HBV RNA could not be assessed in these subjects
- As expected in this NUC-suppressed patient population, there were no discernible changes in HBV DNA, and also, no changes in HBeAg, HBCrAg, and HBsAg
- There were no instances of virologic failure were reported


Table 4. HBV RNA (Log U/mL) Change with 28-day Treatment<sup>a</sup>

	200 mg QD (N=6)	400 mg QD (N=6)	800 mg QD (N=6)	Placebo (N=6)
Baseline	1.18 (0.0, 2.5)	1.57 (0.0, 3.7)	0.83 (0.0, 4.2)	0.96 (0.0, 2.1)
Change at Day 28	-0.81 (-2.3, 0.0) <sup>b</sup>	-1.12 (-2.8, 0.2)	0.10 (-1.9, 0.8) <sup>b</sup>	-0.19 (-1.2, 0.8)

a. Data presented in Mean (Range)  
 b. n = 5

<sup>b</sup> 5 of 6 subjects had HBV RNA < LOD at baseline and the effect of EDP-514 on HBV RNA could not be assessed in these subjects

Figure 4. Antiviral Activity by HBV RNA Change from Baseline Over Time



## CONCLUSIONS

- EDP-514 was generally safe and well-tolerated at 200, 400 and 800 mg doses for 28 days in NUC-suppressed CHB patients
- EDP-514 was rapidly absorbed and EDP-514 exposure increased with increasing multiple doses
- EDP-514 exhibited PK suitable for once daily oral dosing, with C<sub>rough</sub> concentrations reaching up to ~20-fold above the pEC<sub>50</sub>
- At Day 28, EDP-514 demonstrated reductions in circulating HBV RNA levels, consistent with its mechanism of action as an HBV core inhibitor

## REFERENCES

- EDP-514, a novel HBV core inhibitor with potent antiviral activity both *in vitro* and *in vivo*. M Vainé, et al. J Hepatology, VOLUME 70, ISSUE 1, SUPPLEMENT, E474-E475
- EDP-514, a novel pangenotypic class II hepatitis B virus core inhibitor: preliminary results of a phase 1 study in healthy adult subjects. K Larson, et al. J Hepatology, VOLUME 73, SUPPLEMENT 1, S871

## ACKNOWLEDGEMENT

- Special thanks to Yan Zhang (Enanta) for assistance with QC
- We extend our thanks to the subjects who participated in this study and the PRA team for their involvement in the study

## DISCLOSURES

- GLDR, AA, EL, ALC and NA are employees of Enanta Pharmaceuticals, Inc. and may be stockholders